Making savings from the PBS - is deferring the listing of medicines the answer?

Parliament house flag post

Making savings from the PBS - is deferring the listing of medicines the answer?

Posted 4/04/2011 by Rebecca de Boer

In a recent speech, Prime Minister Gillard warned that there would be ‘painful’ cutbacks in the forthcoming Budget. There was no indication of where these cuts might be but it appears that the Government has already made decisions that will slow government expenditure in some programs. Recently, the Government has deferred the listing of products on the Pharmaceutical Benefits Scheme (PBS) until ‘circumstance permit’ and imposed a requirement that all pharmaceuticals that receive a positive recommendation from the Pharmaceutical Benefits Advisory Committee(PBAC) must be considered by Cabinet prior to listing on the PBS. This post explains the recent changes to the process for listing medicines on the PBS and discusses some of the implications of the Government’s decision to defer listing of some medications on the PBS.

Under the National Health Act 1953, pharmaceuticals may not be listed on the PBS without a positive recommendation from the PBAC. The PBAC is an independent expert committee which makes a recommendation based on clinical effectiveness, safety and cost-effectiveness (or value for money). For a product to be listed on the PBS (at a higher price than an equivalent or similar product), it must offer a comparative benefit to what is already listed. This process of economic evaluation determines whether a product offers ‘value for money’ to the Australian taxpayer. Irrespective of the price paid by Government, consumers pay a fixed copayment, $5.60 for concession card holders and $34.20 for general patients.

Once a product receives a positive recommendation from the PBAC, pricing negotiations with the Pharmaceutical Benefits Pricing Authority (PBPA) commence. These negotiations are based on the recommendation from the PBAC. Once the price and any risk sharing agreements are resolved the Minister for Health makes a determination about whether a product is listed on the PBS. Until recently, this was a routine process and it was rare for a product that received a positive recommendation from the PBAC not to be listed on the PBS. An exception to this was in 2002 when the then Minister for Health (Senator Patterson) declined to list Viagra on the PBS, despite a positive recommendation from the PBAC. The advice from the PBAC contained a clear warning that the listing of this product on the PBS may cause a significant budgetary impact on the PBS. This prompted outcry from the pharmaceutical industry who argued that the PBAC was not basing its recommendations on ‘evidence’.

In response to the Government’s decision to defer the listing of products on the PBS, some commentators in the medical and drug industries have argued that the Government was ‘ignoring’ the advice of experts and undermining the role of the PBAC. The announcement to defer the listing of seven products was made together with the announcement to list seven new medicines and vaccines on the PBS from 1 April 2011 as well as 52 new and amended listings. It was noted that the deferred products had existing treatments that were already available on the PBS, although this has been disputed. When making this announcement, the Government noted that it had complied with the strict timeframes for listing (and Cabinet consideration) as set out in the Memorandum of Understanding (MOU) signed with Medicines Australia (the peak lobby group for the patented pharmaceutical sector in Australia). Delays in the listing of products on the PBS have long been criticised by Medicines Australia.

The requirement for Cabinet consideration of products that cost more than $10 million in any of the first four financial years of being listed on the PBS was first introduced in 2001. This has led to delays in the listing of some products on the PBS. Medicines Australia has estimated that the requirement for Cabinet consideration has led to delays of up to ten months. One of the arguments against Cabinet consideration is that drugs which have received a positive recommendation from the PBAC have already been subject to rigorous scrutiny and economic evaluation, in contrast to many other areas of government expenditure.

Expenditure on the PBS has long been of concern to successive governments. The most recent statistics suggest that the PBS expenditure increased 9.2 per cent from June 2008 to June 2009 with a total expenditure of around $7.7 billion for that year. The last Budget estimated that expenditure would increase by 10.6 per cent in 2009-10. PBS prescription volumes only increased by 6.2 per cent and the smaller rise in prescription volumes compared to expenditure was attributed to doctors prescribing newer, more expensive drugs. Both the Howard and the Rudd-Gillard government have introduced measures to curb PBS expenditure such as one-off price cuts, statutory price reductions and the extension of price disclosure arrangements. It is too early to tell whether the most recent reform (signing of MOU with Medicines Australia) will result in considerable savings to Government, although early indications suggest that savings from the 2006 reforms (on which the MOU is based) will not be realised.

The Gillard Government has promised to return the Budget to surplus by 2012-13. Further, there have been reports that Minister Roxon has told the pharmaceutical industry that new drugs will not be listed unless off-setting savings can be found. If true, this combined with the requirement for Cabinet to consider all products that receive a positive recommendation from the PBAC and subsequent deferral of listing most likely will slow PBS expenditure in the short term. It also will have significant implications for access to medicines for Australians. But is this using a blunt axe when a surgeon’s scalpel might be more appropriate?

Australia led the world with the introduction of principles of economic evaluation for pharmaceuticals but is it now time to consider other approaches? The concept of ‘value based pricing’ may warrant further consideration. This approach takes into account the health ‘benefit’ and attempts to calculate the price at which the health benefits are no less than the health services foregone to fund it. It implies that there is an opportunity cost associated with the funding of additional pharmaceuticals (or any additional health services). Although the Government and Medicines Australia have recently committed to series of price cuts to generic medicines under the MOU, it may be that more innovative ways of pricing generic medicines will be required into the future. Specific programs directed towards prescribers and consumer education campaigns may also be required, particularly as pharmaceuticals come off patent and generic medicines are available. Finally, remuneration arrangements for pharmacists could also be reviewed to identify savings.

In an era of budget austerity and proposed health reform, the financing arrangements for the health care system warrant further consideration. The PBS is an area of health policy that has served the taxpayer well, and, overall, it has provided Australians with timely access to a wide range of prescription pharmaceuticals at a cost individuals and the community can afford. But the changing landscape may present opportunities to strengthen the PBS, improve access to prescription pharmaceuticals and ensure better value for money of PBS expenditure.

(Source photo: )

Thank you for your comment. If it does not require moderation, it will appear shortly.
Facebook LinkedIn Twitter Add | Email Print


Flagpost is a blog on current issues of interest to members of the Australian Parliament

Parliamentary Library Logo showing Information Analysis & Advice




refugees asylum immigration Parliament Australian foreign policy elections climate change social security women welfare reform taxation Indigenous Australians Australian Defence Force welfare policy school education higher education private health insurance health financing emissions trading Senate Australian Bureau of Statistics employment people trafficking Asia statistics Middle East illicit drugs gambling health reform federal election 2010 Australian Public Service income management Medicare disability Sport United Nations industrial relations constitution transport politics criminal law Afghanistan health forced labour public service reform environment aged care aid Australian Sports Anti-Doping Agency World Anti-Doping Agency United States federal budget Carbon Pricing Mechanism dental health governance regulation food Fair Work Act voting law enforcement electoral reform OECD Australian Electoral Commission WADA child protection poker machines Australia in the Asian Century steroids National Disability Insurance Scheme detention 43rd Parliament slavery health system domestic violence parliamentary procedure International Women's Day accountability defence capability multiculturalism ASADA Australian Federal Police labour force people smuggling debt international relations New Zealand Australian Crime Commission pharmaceutical benefits scheme Human rights crime China leadership Census election results UK Parliament Papua New Guinea banking corruption pensions children's health Aviation federal election 2013 foreign debt gross debt net debt Senators and Members ALP Newstart Parenting Payment Youth Allowance sea farers Australian economy violence against women vocational education and training military history by-election political parties High Court skilled migration mental health Federal Court terrorist groups science social media Higher Education Loan Program HECS federal state relations youth paid parental leave same sex relationships coal seam gas customs planning doping health risks Gonski Review of Funding for Schooling sex slavery Special Rapporteur Northern Territory Emergency Response social policy Rural and regional trade unions Foreign affairs election timetable Indigenous royal commission Productivity United Kingdom firearms public policy Population ADRV terrorism transparency research and development welfare ASIO intelligence community Australian Security Intelligence Organisation carbon tax mining employer employee renewable energy regional unemployment fishing European Union family assistance United Nations Security Council forestry food labelling Drugs welfare systems Indonesia children Constitutional reform local government codes of conduct terrorist financing homelessness Parliamentary remuneration money laundering Trafficking in Persons Report energy social inclusion paternalism nutrition ODA Defence sitting days electoral divisions Southeast Asia administrative law universities TAFE Ireland citizenship asylum seekers early childhood education Canada Financial sector national security fuel disability employment Tasmania integrity standards NATO Australian Secret Intelligence Service sexual abuse World Trade Organization Australia public health housing affordability bulk billing water health policy Governor-General US economy export liquefied natural gas foreign bribery question time speaker superannuation public housing expertise climate Intergovernmental Panel on Climate Change Department of Agriculture Fisheries and Forestry Pacific Islands reserved seats new psychoactive substances synthetic drugs UNODC carbon markets animal health middle class welfare constitutional recognition of local government referendum consumer laws PISA competition policy US politics language education baby bonus Leaders of the Opposition citizen engagement policymaking Australia Greens servitude Trafficking Protocol forced marriage alcohol entitlements ministries Hung Parliament social citizenship maritime Iran ANZUS regional students school chaplains federal budget 2011-12 salary Medicare Locals primary care Building the Education Revolution marine pollution sustainability prisons police deaths in custody electoral margins electoral pendulum electoral redistribution redistribution NSW redistribution WA redistribution ACT electoral boundaries ASEAN Sustainable Development Goals Double dissolution Senators safety vehicles MYEFO Pathology tertiary education Taiwan Xi Ma meeting family violence government financial advisers financial planners Financial System Inquiry Murray Inquiry China; Economic policy; Southeast Asia; Africa housing Speaker; House of Representatives; Parliament High Court; Indigenous; Indigenous Australians; Native Title ACT Indigenous education Norfolk Island External Territories emissions reduction fund; climate change child care funding refugees immigration asylum procurement Indigenous health e-voting internet voting nsw state elections 44th Parliament 2015 ABS Age Pension Death penalty capital punishment execution Bali nine Bali bombings Trade EU China soft power education Fiji India Disability Support Pension Antarctica Diplomacy by-elections state and territories Bills anti-corruption fraud bribery corporate ownership whistleblower G20 economic reform innovation Members of Parliament Scottish referendum Middle East; national security; terrorism social services Criminal Code Amendment (Misrepresentation of Age to a Minor) Bill 2013 online grooming sexual assault of minors ACT Assembly smoking plain packaging tobacco cigarettes Asia; Japan; international relations Work Health and Safety Migration; asylum seekers; regional processing China; United States; international relations fiscal policy Racial Discrimination Act; social policy; human rights; indigenous Australians Foreign policy Israel Palestine asylum refugees immigration political finance donations foreign aid Economics efficiency human rights; Racial Discrimination Act employment law bullying Animal law; food copyright Australian Law Reform Commission industry peace keeping contracts workplace policies same-sex marriage disorderly conduct retirement Parliament House standing orders prime ministers First speech defence budget submarines workers Somalia GDP world heritage political engagement leave loading Trade; tariffs; safeguards; Anti-dumping public interest disclosure whistleblowing Productivity Commission limitation period cancer gene patents genetic testing suspension of standing and sessional orders live exports infant mortality honorary citizen railways disciplinary tribunals standard of proof World Health Organisation arts international students skilled graduate visas temporary employment visas apologies roads Italy national heritage NHMRC anti-dumping Rent Assistance obesity evidence law sacrament of confession US presidential election international days DFAT UN General Assembly deregulation Regulation Impact Statements small business Breaker Morant regional engagement social determinants of health abortion Members suspension workplace health and safety marine reserves hearing Victoria astronomy resources sector YMCA youth parliament Korea rebate Australian Greens presidential nomination Racial Discrimination Act political parties preselection solar hot water Financial Action Taskforce Horn of Africa peacekeeping piracy Great Barrier Reef Stronger futures political financing political education Social Inclusion Board early childhood National Quality Framework for Early Childhood Education and Care Murray-Darling Basin sanctions Norway hospitals republic President Barack Obama Presidential visits qantas counselling Korean peninsula Work Choices biosecurity hendra environmental law federalism federation preselection therapeutic goods Therapeutic Goods Administration plebiscites computer games pests suicide nuclear COAG Ministerial Councils floods ADHD stimulant medication advertising electricity extradition conscience votes poverty preventative health rural health coastal erosion Parliamentary Budget Office work-life balance

Show all
Show less
Back to top